Literature DB >> 18832739

Subsets of myeloid-derived suppressor cells in tumor-bearing mice.

Je-In Youn1, Srinivas Nagaraj, Michelle Collazo, Dmitry I Gabrilovich.   

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of cells that play a critical role in tumor associated immune suppression. In an attempt to identify a specific subset of MDSC primarily responsible for immunosuppressive features of these cells, 10 different tumor models were investigated. All models showed variable but significant increase in the population of MDSC. Variability of MDSC expansion in vivo matched closely the effect of tumor cell condition medium in vitro. MDSC consists of two major subsets of Ly6G(+)Ly6C(low) granulocytic and Ly6G(-)Ly6C(high) monocytic cells. Granulocytic MDSC have increased level of reactive oxygen species and undetectable level of NO whereas monocytic MDSC had increased level of NO but undetectable levels of reactive oxygen species. However, their suppressive activity per cell basis was comparable. Almost all tumor models demonstrated a preferential expansion of granulocytic subset of MDSC. We performed a phenotypical and functional analysis of several surface molecules previously suggested to be involved in MDSC-mediated suppression of T cells: CD115, CD124, CD80, PD-L1, and PD-L2. Although substantial proportion of MDSC expressed those molecules no differences in the level of their expression or the proportion, positive cells were found between MDSC and cells from tumor-free mice that lack immune suppressive activity. The level of MDSC-mediated T cell suppression did not depend on the expression of these molecules. These data indicate that suppressive features of MDSC is caused not by expansion of a specific subset but more likely represent a functional state of these cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832739      PMCID: PMC2575748          DOI: 10.4049/jimmunol.181.8.5791

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells.

Authors:  D I Gabrilovich; M P Velders; E M Sotomayor; W M Kast
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

2.  Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion.

Authors:  Therese A Dietlin; Florence M Hofman; Brett T Lund; Wendy Gilmore; Stephen A Stohlman; Roel C van der Veen
Journal:  J Leukoc Biol       Date:  2007-02-16       Impact factor: 4.962

Review 3.  Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.

Authors:  James E Talmadge
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

4.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.

Authors:  Pratima Sinha; Virginia K Clements; Amy M Fulton; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

5.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity.

Authors:  Kiavash Movahedi; Martin Guilliams; Jan Van den Bossche; Rafael Van den Bergh; Conny Gysemans; Alain Beschin; Patrick De Baetselier; Jo A Van Ginderachter
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

6.  CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis.

Authors:  Bing Zhu; Yoshio Bando; Sheng Xiao; Kaiyong Yang; Ana C Anderson; Vijay K Kuchroo; Samia J Khoury
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

7.  Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function.

Authors:  Ping-Ying Pan; George X Wang; Bingjiao Yin; Junko Ozao; Teresa Ku; Celia M Divino; Shu-Hsia Chen
Journal:  Blood       Date:  2007-09-20       Impact factor: 22.113

8.  Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses.

Authors:  Ingo Fricke; Noweeda Mirza; Jakob Dupont; Craig Lockhart; Autumn Jackson; Ji-Hyun Lee; Jeffrey A Sosman; Dmitry I Gabrilovich
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

9.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

10.  MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis.

Authors:  Matthew J Delano; Philip O Scumpia; Jason S Weinstein; Dominique Coco; Srinivas Nagaraj; Kindra M Kelly-Scumpia; Kerri A O'Malley; James L Wynn; Svetlana Antonenko; Samer Z Al-Quran; Ryan Swan; Chun-Shiang Chung; Mark A Atkinson; Reuben Ramphal; Dmitry I Gabrilovich; Wesley H Reeves; Alfred Ayala; Joseph Phillips; Drake Laface; Paul G Heyworth; Michael Clare-Salzler; Lyle L Moldawer
Journal:  J Exp Med       Date:  2007-06-04       Impact factor: 14.307

View more
  773 in total

1.  Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells.

Authors:  Michael W Pickup; Philip Owens; Agnieszka E Gorska; Anna Chytil; Fei Ye; Chanjuan Shi; Valerie M Weaver; Raghu Kalluri; Harold L Moses; Sergey V Novitskiy
Journal:  Cancer Immunol Res       Date:  2017-08-03       Impact factor: 11.151

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

3.  Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis.

Authors:  Hisako Kayama; Yoshiyasu Ueda; Yukihisa Sawa; Seong Gyu Jeon; Ji Su Ma; Ryu Okumura; Atsuko Kubo; Masaru Ishii; Taku Okazaki; Masaaki Murakami; Masahiro Yamamoto; Hideo Yagita; Kiyoshi Takeda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-07       Impact factor: 11.205

4.  Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis.

Authors:  Huanfa Yi; Chunqing Guo; Xiaofei Yu; Daming Zuo; Xiang-Yang Wang
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

5.  In vivo ablation of plasmacytoid dendritic cells inhibits autoimmunity through expansion of myeloid-derived suppressor cells.

Authors:  Marianna Ioannou; Themis Alissafi; Louis Boon; Dimitrios Boumpas; Panayotis Verginis
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

Review 6.  Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.

Authors:  Bruce R Blazar; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Blood       Date:  2018-05-04       Impact factor: 22.113

7.  Myeloid-Derived Suppressor Cells Impair B Cell Responses in Lung Cancer through IL-7 and STAT5.

Authors:  Yong Wang; Cara C Schafer; Kenneth P Hough; Sultan Tousif; Steven R Duncan; John F Kearney; Selvarangan Ponnazhagan; Hui-Chen Hsu; Jessy S Deshane
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

8.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

Review 9.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

10.  Induction of myelodysplasia by myeloid-derived suppressor cells.

Authors:  Xianghong Chen; Erika A Eksioglu; Junmin Zhou; Ling Zhang; Julie Djeu; Nicole Fortenbery; Pearlie Epling-Burnette; Sandra Van Bijnen; Harry Dolstra; John Cannon; Je-in Youn; Sarah S Donatelli; Dahui Qin; Theo De Witte; Jianguo Tao; Huaquan Wang; Pingyan Cheng; Dmitry I Gabrilovich; Alan List; Sheng Wei
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.